This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.
Dysphagia is a complex condition common in a number of diagnoses including stroke, Parkinson's disease, head and neck cancer, dementia, learning disabilities and gastric/oesophageal motility disorders. A modified textured diet and/or fluid is considered as an effective intervention in management of dysphagia. The International Dysphagia Diet Standardisation Initiative (IDDSI) have developed a new framework around the terms and descriptors used in the management of individuals with dysphagia. Malnutrition is very common in patients with dysphagia and the use of pre-thickened oral nutritional supplements (ONS) has been found as an effective way to manage this. However, due to impairment in the swallow process, dysphagic patients require pre-thickened oral nutritional supplement to ensure safe consumption of these nutritional supplements. 40 participants, requiring a new pre-thickened oral nutritional supplement in line with the new IDDSI framework recruited from hospitals, outpatients clinics, care homes, community hospitals, community dietetic/speech and language therapy services or stroke rehabilitation units will receive the ready-to-use oral nutritional supplement for a 4 week intervention period. This study aims to primarily evaluate gastro-intestinal tolerance, with secondary outcomes including compliance, acceptability, nutrient intake, anthropometry and safety.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
40
ready-to-use nutritional supplement drink to be taken daily for 28 days
Aneurin Bevan University Health Board
Caerleon, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Dudley Group NHS Trust
Dudley, United Kingdom
Cwm Taf University Health Board
Llwynypia, United Kingdom
Gastrointestinal Tolerance
Gastro-intestinal tolerance will be assessed daily throughout a 3 day baseline period before starting the study ONS and at the end of each week (day 10, day 17, day 24, day 31) using a standardised GI tolerance questionnaire including questions on number of bowel movements per day, other gastrointestinal symptoms such as flatulence, bloating, burping and abdominal discomfort. Patient-reported gastrointestinal symptoms with scale range for each symptom as s scale range minimum = none, maximum = severe. Change of symptom from baseline scale minimum = no change, maximum = worse.
Time frame: Day 1, Day 2, Day 3, Day 10, Day 17, Day 24 and Day 31
Compliance
Daily questionnaire on amount of nutritional drink prescribed and amounts actually consumed. Amount of daily ONS actually consumed scale minimum = 0%, maximum = 100%
Time frame: Once during baseline period (Day 1) and then daily through intervention period (Days 4-31)
Acceptability: Brief tick-box questionnaire
Brief tick-box questionnaire on overall liking and acceptability of product, including texture and feel of nutritional drink, flavor and ease of use. Scale minimum = dislike very much, maximum = like very much Scale minimum = very inconvenient, maximum = very convenient Scale minimum = very difficult, maximum = very easy
Time frame: Day 1, Day 17, Day 31
Anthropometry
Measurements of height and weight with Body Mass Index (BMI) calculated at baseline and end of study.
Time frame: Day 1 and Day 31
Nutrient intake
Three dietary recalls relating to the the past 24 hours of Day 1, Day 17 and Day 31 to capture all food and fluids consumed. This will subsequently be analysed in dietary software.
Time frame: Day 1, Day 17 and Day 31
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Croydon Health NHS Trust
London, United Kingdom
Lewisham and Greenwich NHS Foundation Trust
London, United Kingdom
Great Western Hospitals NHS Foundation Trust
Swindon, United Kingdom
Weston Area Health Trust
Weston-super-Mare, United Kingdom
Safety (Adverse events reporting)
Reporting of any adverse events that occur throughout study.
Time frame: 31 days.